A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy
Phase of Trial: Phase II/III
Latest Information Update: 26 Mar 2018
Price : $35 *
At a glance
- Drugs Eleclazine (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Pharmacodynamics; Registrational
- Acronyms LIBERTY-HCM
- Sponsors Gilead Sciences
- 24 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 01 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
- 25 Jan 2017 This trial was completed in Italy (end date: 2016-12-08), according to European Clinical Trials Database.